























		DKK3	 is	a	 tumour	suppressor	gene	encoding	a	secreted	protein,	Dkk-3,	which	 is	 found	 in	





WPMY-1	 cell	 co-culture	 and	 WPMY-1	 cell	 conditioned	 media	 reduced	 proliferation	 and	
rescued	acinar	morphogenesis	of	the	DKK3-silenced	RWPE-1	prostate	epithelial	cells	in	a	Dkk-
3-dependent	manner.	DKK3-silenced	WPMY-1	cell	conditioned	media	increased	PC3	prostate	




cell	 conditioned	 media.	 Purified	 recombinant	 TGFBI,	 but	 not	 ECM1,	 increased	 PC3	 cell	
invasion,	and	purified	ECM1,	but	not	TGFBI,	increased	normal	acinar	morphogenesis	of	DKK3-
silenced	RWPE-1	cells.		
	 	 Immunohistochemical	 analysis	 of	 Dkk-3,	 TGFBI	 and	 ECM-1	 in	 prostate	 cancer	 showed	
significantly	lower	levels	of	Dkk-3	in	prostate	cancer	than	in	benign	epithelium	and	in	tumour	














		The	 experiments	 carried	 out	 by	 others	 were	 as	 follows:	 Dr	 Yoshiaki	 Kawano	 (Imperial	
















		The	copyright	of	 this	 thesis	 rests	with	 the	author	and	 is	made	available	under	a	Creative	
Commons	Attribution	Non-Commercial	No	Derivatives	licence.	Researchers	are	free	to	copy,	
distribute	or	transmit	the	thesis	on	the	condition	that	they	attribute	it,	that	they	do	not	use	






























































































































































































Table	 6.3	 Statistical	 analysis	 of	 TGFBI	 expression	 in	 benign	 prostate	 and	 prostate	 cancer;	 benign	
stroma	(NS),	cancer	stroma	(CS),	benign	epithelium	(epi)	
Figure	6.7	Scoring	system	for	ECM-1	
Table	 6.4	 Statistical	 analysis	 of	 ECM-1	 expression	 in	 benign	 prostate	 and	 prostate	 cancer.	 Benign	
epithelium	(epi)	















































































































































































One	 strategy	 that	 might	 help	 us	 win	 this	 battle	 is	 the	 modulation	 of	 the	 host	 micro-
environment	 so	 that	 it	 becomes	 a	 more	 hostile	 environment	 for	 cancer	 cells.	 Autocrine	
factors	and	their	receptors	mediate	communication	between	epithelial	cells	and	their	stromal	






























the	 secretory	 and	 basal	 epithelia	 (Figure	 1.2).	 The	 secretory	 epithelium	 consists	 of	 tall	
columnar	 cells	 that	 are	 responsible	 for	 the	 secretion	 of	 prostate-specific	 antigen	 (PSA),	
prostatic	acid	phosphatase	(PAP)	and	kallikrein-related	peptidase	2	(KLK2),	which	are	found	
in	the	seminal	fluid	[9,	10].	The	basal	layer	consists	of	cuboidal	epithelium	and	is	believed	to	





The	 basal	 cell	 layer	 is	 undifferentiated,	 androgen-independent	 and	 does	 not	 exhibit	 any	
secretory	activity,	in	contrast	to	the	secretory	epithelial	cell	layer	[12,	13].		
		The	basal	cell	layer	is	embedded	in	the	basement	membrane	that	separates	the	epithelial	
cells	 from	 the	 stroma.	 Neuroendocrine	 (NE)	 cells	 are	 another	 type	 of	 cell	 that	 are	 found	
scattered	 in	 the	epithelial	 layers	 [14].	 The	origin	of	NE	 cells	 is	 unclear,	with	 some	 studies	





types,	which	 include	 fibroblasts,	 smooth	muscle	 cells,	 lymphatic	 cells	 and	nerve	 cells.	 The	
interactions	of	the	three	types	of	cells	in	the	epithelium	(secretory,	basal	and	NE	cells)	with	



















15%	 of	 patients	who	 experience	 disease	 recurrence	 either	 locally	 or	 systemically	 and	 are	
destined	to	die	from	the	disease	[24].	A	refined	classification	scheme	is	required	to	assist	in	
early	diagnosis	and	proper	intervention	of	the	high-risk	PCa	population.	In	addition,	a	refined	





















		The	 aggressive	histopathological	 phenotype	of	 PCa	 is	 acquired	 through	multiple	 steps	of	
epigenetic	 and	 genetic	 modifications	 that	 facilitate	 cancer	 cell	 survival,	 proliferation	 and	
capacity	 for	 invasion	 [35].	 These	 modifications	 are	 associated	 with	 alterations	 in	 many	
biological	 aspects	 (Table	 1.1).	 First,	 increased	 systemic	 levels	 of	 growth	 factors	 –	 such	 as	
insulin-like	growth	factor	(IGF)	-1	and	IGF-2,	mainly	secreted	by	the	liver,	which	correlate	with	
PSA	 levels	>	10	and	high	Gleason	 score	and	can	promote	proliferation	 [36].	 Second,	 gene	
mutations,	 such	as	 in	PTEN,	which	normally	 counteracts	 activation	of	phosphoinositide	3-
kinase	(PI3K)	and	its	downstream	mediators	Akt	and	mTOR,	which	promotes	protein	synthesis	
and	enhances	tumour	growth	[37].	Third,	activation	of	transcription	factors,	such	as	AR	and	
c-Myc,	 whose	 genes	 are	 frequently	 amplified	 in	 PCa	 [38].	 AR	 is	 a	 110	 kDa	 zinc	 finger	
transcription	 factor	 and	 its	 stimulation	 initiates	 upon	 the	 binding	 of	 its	 ligands,	 mainly	





found	 in	 40–60%	 of	 PCa	 patients,	 result	 in	 androgen-dependent	 expression	 of	 the	
transcription	factor	ERG	[44]	and	contribute	to	androgen	resistance	and	PCa	progression	[45,	
46].	Fourth,	increased	expression	of	transcriptional	co-regulators,	such	as	steroid	receptor	co-






















		Prostate	 cancer	 is	 likely	 initiated	 from	 the	 epithelial	 compartment	 after	 critical	 genetic	
and/or	 epigenetic	 changes	 that	 accumulate	 throughout	 cancer	 progression.	However,	 the	
micro-environment	 also	 plays	 a	 role	 and	 can	 either	 accelerate	 or	 reduce	 cancer	
aggressiveness,	 resistance	to	therapy,	 immune	escape	and	metastasis	 [49].	 In	general,	 the	






the	 ECM).	 Many	 growth	 factors	 and	 cytokines	 influence	 the	 epithelial	 to	 mesenchymal	
transition	 (EMT).	 the	 process	 in	 which	 epithelial	 cells	 lose	 their	 polarity	 and	 adhesion	 to	
adjacent	cells	and	acquire	migratory	and	invasive	features,	becoming	more	like	mesenchymal	
cells	 [54].	 EMT	 is	 driven	 largely	 by	 transforming	 growth	 factor	 beta	 (TGF-β),	 but	 also	 by	
hepatocyte	 growth	 factor	 (HGF),	 fibroblast	 growth	 factor	 (FGF),	 epidermal	 growth	 factor	
(EGF),	 IGF	 and	 interleukin	 1	 alpha	 (IL-1α)	 [55-59].	 EMT	 endows	 epithelial	 cells	 with	
mesenchymal	features,	such	as	an	increased	expression	of	SMA,	vimentin,	N-cadherin,	type	
I/III	collagen,	fibronectin	and	fibroblast-specific	protein	1	(FSP-1)	and	reduces	expression	of	
epithelial	markers,	 such	as	cytokeratin	18,	 zona	occludens	 (ZO)-1,	mucin	1	and	E-cadherin	
	 24	
[33].	 Another	 biological	 reflection	 of	 TGF-β	 signalling	 is	 the	 regulation	 of	 the	 zinc	 finger	
transcription	factors	Snail,	Zeb-1	and	Slug,	increased	expression	of	which	promotes	EMT	and	
contributes	to	poor	clinical	prognosis	[34].	









adenocarcinoma	 [61,	62].	However,	 the	conversion	of	benign	 stroma	 to	cancer	 stroma	by	
signals	from	cancer	cells	creates	a	supportive	environment	for	cancer	cell	invasion	[62,	63].	
For	example,	P62	 is	a	 tumour	 suppressor	protein	 that	becomes	downregulated	 in	 tumour	
stroma,	altering	the	metabolism	through	the	regulation	of	mTORC1	and	c-Myc,	resulting	in	






environment,	 such	 as	 the	 expression	 and	 secretion	 of	 either	 pro-tumorigenic	 or	 tumour	
suppressive	factors,	the	deposition	of	the	ECM	(desmoplastic	response),	the	modulation	of	
immune	responses,	the	regulation	of	EMT,	epigenetic	changes	and	the	promotion	of	a	cancer	













and	 inflammation	 that	 express	 smooth	 muscle	 actin	 (SMA)	 and	 collagen	 [48].	 They	 can	
become	 permanently	 differentiated	 and	 a	 predominant	 cell	 type	 in	 reactive	 stroma.	
Differentiated	 myofibroblasts	 are	 also	 called	 CAFs	 [49,	 50].	 In	 addition,	 the	 micro-
environment	and	tumour-derived	factors	direct	the	CAF	phenotype.	Thus,	the	CAF	phenotype	
and	the	state	of	differentiation	and	activation	vary	from	one	tissue	to	another.	This	is	called	













and	 stimulates	 endothelial	 precursor	 cell	 invasion	 into	 tumour	 tissue	 [66],	 and	 CXCL14	
activates	 fibroblasts	 in	 the	PCa	micro-environment	 in	an	autocrine	manner	 [67].	 In	breast	
cancer,	breast	cancer	cells	secrete	Wnt-7a	to	increase	CAF	recruitment	and	activation	[68].	
The	proposed	mechanism	is	the	indirect	activation	of	TGF-β	signalling	in	stromal	fibroblasts.	
			In	 contrast,	 other	 studies	 show	 that	 CAFs	 and	 normal	 fibroblasts	 (NFs)	 restrict	 tumour	
progression,	depending	on	tissue	type	and	tissue	context.	Thus,	both	stroma	and	cancer	type	
should	 be	 taken	 into	 consideration	 to	 determine	 the	 end	 response	 of	 CAF/NF-cancer	 cell	
crosstalk.	One	study	demonstrated	the	impact	of	Slit-2	ligands	expressed	by	NFs	and	CAFs,	
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which	 bind	 to	 Robo-1	 on	 breast	 cancer	 cells	 to	 reduce	 tumorigenesis	 by	 interfering	with	
PI3K/β-catenin	signals	[69].	Cancer	cells	that	do	not	express	Robo-1	show	increased	tumour	
aggressiveness.	Slit-2	 is	also	correlated	with	overall	survival	and	metastasis.	Another	study	
demonstrated	 a	 dual	 function	 of	 fibroblast-derived	Wnt-3a,	 in	 which	Wnt-3a	 inhibits	 the	
growth	of	 triple	negative	breast	 cancer	 cells	but	 increases	 the	growth	of	 cancer	 cells	 that	
overexpress	the	human	EGF	receptor-2	(HER2)	[70].	
			Some	studies	have	revealed	the	consequences	of	alteration	 in	 the	expression	of	stromal	
factors	 in	 terms	 of	 predicting	 patient	 relapse	 and	 tumour	 aggressiveness,	 based	 on	
race/ethnicity	[71,	72].	For	example,	PCa	is	more	aggressive	in	African	American	men,	and	a	







These	 22	 nucleotides	 non-coding	 RNAs	 regulate	 gene	 expression	 by	 inhibiting	 the	
transcription	and/or	the	translation	of	mRNAs.	For	example,	miR-409,	miR-379	and	miR-154,	
which	 are	 located	 together	 on	 human	 chromosome	 14,	 are	 transmitted	 via	 extracellular	
vesicles	 (EVs)	 from	 CAFs	 to	 the	 prostate	 epithelium	 in	 a	 paracrine	 manner	 and	 enhance	
tumour	 growth	 in	 a	 PCa	mouse	model	 [76,	 77].	 In	 addition,	 this	 group	of	miRs	 promotes	
stem/progenitor	cell	phenotype	in	PCa	and	enhances	EMT	in	the	prostate	epithelium	[78].		
Activation	of	fibroblasts	into	myofibroblasts	(CAFs)	






in	 pathological	 states,	 such	 as	 cancer,	 keloids,	 scleroderma,	 rheumatoid	 arthritis	 and	
	 28	
hypertrophic	 scars	 [80].	 TGF-β	 signalling	 is	 a	 key	 driver	 of	 fibroblast	 to	 myofibroblast	
differentiation	and	the	continuous	activation	of	TGF-β	signalling	is	observed	in	pathological	
states	 [81-83].	 In	 addition,	 gene	 expression	 profiling	 has	 shown	 that	 the	 major	 genes	
regulated	by	TGF-β	and	MAPK	are	more	highly	expressed	in	CAFs	compared	to	NFs	[84,	85].	
		Myofibroblasts	 have	 several	 characteristic	 features,	 including	 the	 expression	 of	 SMA,	
proliferative	activity,	high	motility,	secretion	of	cytokines	and	the	ability	to	remodel	the	ECM	












irreversibly	 differentiated	 myofibroblast	 was	 predominantly	 accepted;	 however,	 in	 fact,	








secondary	 (metastatic)	 sites	 [101,	 102].	 The	 fundamental	 elements	 involved	 in	 the	 two	
compartment	 interactions	 are	 growth	 factors,	 cytokines,	 pro-angiogenic	 factors	 and	
components	 of	 the	 ECM	 [103,	 104].	 The	 TGF-β	 signalling	 pathway	 is	 potent	 and	
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like	 kinase	 (ALK5))	 [110].	 Activated	 receptors	 propagate	 signalling	 to	 the	 nucleus	 via	
phosphorylation	of	the	receptor	Smads	(R-Smads)	–	Smad2	and	Smad3,	as	well	as	Smads	1,	5,	
8	–	which	bind	to	Smad4	to	regulate	gene	expression	(Figure	1.5).	This	process	can	be	blocked	
by	 inhibitory	Smads	 (I-Smads),	 Smad6	and	Smad7	 [110].	TGF-β	 signalling	can	be	canonical	
(Smad-dependent),	 activating	 gene	 expression	 via	 Smads,	 and	 non-canonical	 (Smad-
independent),	acting	through	MAPK	kinase,	Rho-like	GTPases	and	PI3K/AKT	[111]	(Figure	1.5).	
		TGF-β	signalling	activity	switches	from	tumour	suppressive	to	tumour	promoting	depending	
on	 the	 tumour	 stage	 [112,	 113].	 TGF-β	 is	 anti-proliferative	 and	 pro-apoptotic	 in	 benign	
prostate	 epithelial	 cells,	 with	 activity	 through	 c-Myc	 and	 cyclin-dependent	 kinase	 (CDK)	









Low	 concentrations	 of	 TGF-β1	 (0.1	 ng/ml)	 promote	 auto-induction	 of	 TGF-β	 signalling	 in	
benign	prostate	and	PCa,	while	higher	concentrations	(10	ng/ml)	induce	the	recruitment	of	
protein	 phosphatase	 2A	 (PP2A),	 leading	 to	 the	 termination	of	 both	MAPK/ERK	 and	 TGF-β	
signalling	 [117].	 In	 PCa	 cells,	 TGF-β	 auto-induction	 is	 associated	 with	 a	 defect	 in	 the	






dominant-negative	 TβRII	 increases	 prostate	 epithelial	 cell	 proliferation	 and	 induces	 EMT,	
metastasis	 and	 angiogenesis	 [123].	 In	 addition,	 an	 SNP	 variant	 of	 TβRII	 correlates	 with	 a	
higher-Gleason-score	PCa	and	is	a	risk	factor	of	relapse	after	ADT	in	CRPC	patients	[124,	125].	
		TGF-β	is	secreted	by	the	bone	matrix	at	sites	of	bone	metastasis,	altering	the	homeostatic	
balance	 of	 bone	 formation	 towards	 increased	 bone	 destruction	 [126].	 In	 addition,	 TGF-β	
enhances	the	expression	of	genes	that	promote	metastasis	[127]	and	inhibition	of	the	TGF-β	
signalling	reduces	breast	cancer	bone	metastasis	in	a	mouse	model	[126].	An	important	TGF-




hypermethylation	 in	many	 gene	 promoters,	 including	 those	 of	 the	 TGF-β 	 receptors,	 and	
thereby	reducing	their	expression	[129].	Another	proposed	mechanism	of	inhibiting	TβRI	in	







		There	 is	 remarkable	 crosstalk	 between	AR	 and	 TGF-β	 signalling.	 Androgen	 signalling	 can	
regulate	 TGF-β	 signalling	 in	 PCa	 cells	 at	 the	 early	 stages	 and	 in	 advanced	 PCa	 [132].	 For	
example,	DHT	promotes	the	effects	of	TGF-β/TGFβRII	on	increasing	apoptosis	and	cell	cycle	





in	 many	 types	 of	 cancer	 [135,	 136],	 as	 well	 as	 in	 stromal	 fibroblasts	 [137,	 138].	 The	 AR	
inhibitors	 bicalutamide	 and	 enzalutamide	 have	 been	 found	 to	 increase	 invasiveness	 by	
stimulating	TGF-β	activation	of	MMP9	[139],	suggesting	that	simultaneous	inhibition	of	both	
AR	and	TGF-β	signalling	may	not	always	be	beneficial		
		MiRs	 also	 contribute	 to	 PCa	 progression	 [140],	 partly	 by	 regulating	 TGF-β	 signalling.	 For	












ductal	 system	 preserves	 the	 composition	 and	 cellular	 haemostasis	 of	 the	 proximal,	





size	 and	 composition	 of	 the	 prostate	 gland	 by	 regulating	 the	 growth	 and	 proliferation	 of	
prostate	epithelial	cells.	Disturbance	in	these	patterns	of	expression	can	lead	to	pathological	
conditions,	such	as	BPH	and	PCa	[50,	150,	151].		





		The	 adult	 prostate	 is	 arranged	 as	 individual	 ductal	 systems	 consisting	 of	 the	 proximal,	
intermediate,	 and	 distal	 regions	 [152].	 The	 stability	 of	 these	 regions	 is	 maintained	 in	 a	
homeostatic	state	through	strictly	regulated	TGF-β	signalling	cross	talk	between	the	stromal	
and	epithelial	compartments	[152].	The	epithelium	of	the	distal	duct	consists	of	proliferative	










		TGF-β	 signalling	 is	 a	 potent	 regulator	 of	 PCa	 aggressiveness	 and	 progression,	 due	 to	 its	
effects	on	myofibroblast	differentiation	and	the	expression	of	VEGF	 [153,	154].	Silibinin,	a	
compound	extracted	from	milk	thistle	seeds	that	is	under	investigation	for	cancer	treatment,	
significantly	 reduces	 fibroblast	 differentiation	 into	 myofibroblasts	 by	 inhibiting	 TGF-β2	





reduces	 the	 production	 of	 VEGF	 in	 PCa	 cells	 by	 inhibiting	 TGF-β/Smad	 signalling	 [154].	 In	
addition,	 TGF-β	 can	 affect	 the	 stromal	micro-environment	 through	 its	 effects	 on	 immune	
system	cells.	Infiltrated	inflammatory	cells	in	the	tumour	micro-environment	activate	the	CAF	










remodelling	 [158]	and	both	are	upregulated	by	TGF-β	signalling	 in	PCa	 [159].	At	 the	same	
time,	Dkk-3	is	a	potent	regulator	of	TGF-β/Smad	signalling	in	prostate	epithelial	cells,	where	
it	maintains	normal	prostate	morphogenesis	and	epithelial	proliferation	by	attenuating	TGF-
β	 signalling	 [160].	 Silencing	 of	 Dkk-3	 increases	 the	 levels	 of	 MMP2	 in	 RWPE-1	 prostate	
epithelial	cells	and	of	MMP9	 in	primary	prostate	epithelial	cells	 [161].	Dkk-3	may	regulate	
MMP	activity	 via	 its	effects	on	TGF-β	 signalling	 [162],	 and	as	a	 result	has	 the	potential	 to	
restrict	prostate	cancer	metastasis.	 Interestingly,	control	of	MMP	activity	 is	also	important	












Dkk-4	 [165].	 The	Cys2	domain	has	a	 colipase	 fold,	which	 is	 found	 in	 colipases,	where	 it	 is	









also	 having	 no	 overt	 phenotype	 [170].	 However,	 Soggy	 is	 expressed	 primarily	 in	
spermatocytes	and	 the	 trophectoderm	[163,	171].	 In	 the	mouse	prostate,	Dkk-3	has	been	
detected	near	the	cell	surface	of	the	inner	lumen	of	the	prostate	gland	[172].	The	prostates	








downregulated	 in	 cancer.	 They	 include	Wnt	 inhibitory	 factor	 1	 (WIF-1),	 secreted	 frizzled-
related	 family	 proteins	 (sFRPs)	 and	 Dkk	 family	 proteins	 [2].	 The	 effects	 of	 Dkk-3	 on	Wnt	
signalling	vary:	Dkk-3	has	been	reported	to	inhibit	Wnt	signalling	in	osteosarcoma	cell	lines,	
malignant	glioma	cells,	breast	cancer	cells	and	non-small	cell	lung	cancer	(NSCLC)	cells	[2].	In	







by	 the	 transfection	 of	 limiting	 amounts	 of	 β-catenin,	 and	 this	 could	 be	 inhibited	 by	 co-
transfected	Dkk-3	(61),	suggesting	that	endogenous	Dkk-3	indirectly	represses	β-catenin/Tcf	
signalling.	In	addition,	a	recent	study	in	mice	found	an	alternative	start	site	in	the	mouse	Dkk3	







10.	Additionally,	Dkk3	has	been	found	to	 limit	autoimmunity	 in	a	model	of	systemic	 lupus	
erythematosus.		
		MSCs	play	a	pivotal	 role	 in	modulating	 the	 immune	micro-environment.	Generally,	MSCs	
limit	many	aggressive	types	of	systemic	immune	responses,	such	as	is	seen	in	autoimmune	
disease,	host-versus-graft	disease,	and	auto-encephalitis	[179].	While	wild-type	MSCs	inhibit	
immune	 responses	 against	 transplanted	 tumours,	 Dkk3-deficient	 MSCs	 do	 not	 affect	 the	
rejection	process.	Increased	CD8+	T	cells	and	reduced	macrophage	infiltration	were	observed	
in	 tumours	 inoculated	 together	 with	 Dkk3-deficient	 MSCs.	 Thus,	 Dkk-3	 could	 alter	 the	
composition	of	 the	 tumour	 stroma,	 thereby	 supporting	 the	MSC-mediated	 suppression	of	
immune	responses	against	these	tumour	transplants	[180].	
	Dkk-3	also	modulates	peripheral	CD8	T	cell	tolerance.	T	cells	are	normally	tolerant	to	self-


















		Tsuji	 et	 al.	 first	 identified	 DKK3	 as	 a	 gene	 located	 at	 chromosome	 11p15	 with	 reduced	
expression	 in	 immortalised	 cells	 (REIC)	 in	 cancer	 cell	 lines,	 and	 also,	 for	 the	 first	 time	 in	
primary	samples	of	 lung	cancer,	where	63%	of	specimens	showed	 low	expression	of	DKK3	
mRNA	 [188].	 Downregulation	 of	 DKK3	 was	 later	 observed	 in	 a	 wide	 variety	 of	 primary	
haematological	and	solid	cancers,	with	remarkably	 low	expression	 in	a	high	proportion.	 In	
PCa,	DKK3	promoter	methylation	was	observed	in	68%	of	tumours,	correlating	with	significant	
downregulation	 of	 DKK3	 mRNA	 expression	 [189].	 Moreover,	 in	 testicular	 cancer,	 the	
estimated	downregulation	of	DKK3	is	100%	[190]	(Table	1.2).	However,	in	some	cancers	DKK3	





interferes	 with	 the	 access	 of	 transcriptional	 factors	 and	 RNA	 polymerase	 II.	 In	 addition,	











[160,	 197].	 Specific	 mammalian	 Dkk-3	 receptors	 have	 still	 not	 been	 identified,	 further	
contributing	to	the	mystery	of	the	Dkk-3	function.	However,	zebrafish	Dkk3	has	been	found	
to	bind	to	an	integrin	family	member	(60).		Recently,	a	novel	receptor	for	the	Cys-1	domain	in	





The	 Cys2	 domain	 appears	 to	 be	 important	 for	 Dkk-3	 activity	 in	 PCa,	 as	 it	 inhibits	 TGF-β-









downregulated	mesenchymal	markers,	 such	as	Snail1	 [201].	 In	addition,	 the	expression	of	
Dkk-3	has	been	shown	to	prevent	metastasis	in	osteosarcoma	(OS).	OS	is	associated	with	a	
high	rate	of	distant	metastasis,	particularly	to	the	lung,	and	poor	overall	survival	[202].	Ectopic	
expression	 of	 DKK3	 significantly	 reduced	 metastasis	 to	 the	 lung	 by	 reducing	 EMT,	 as	
demonstrated	by	the	 increased	expression	of	epithelial	markers	(E-cadherin,	keratin	8	and	





tissue.	 For	 example,	 high	 Dkk-3	 expression	 in	 head	 and	 neck	 squamous	 cell	 carcinoma	
correlates	with	 reduced	metastasis-free	 survival	 [205].	Moreover,	DKK3	overexpression	 in	
these	cells	 increased	proliferation,	migration	and	 invasion	by	activating	PI3K/Akt	signalling	
[206].	
		In	 PCa,	Dkk-3	 is	 tumour	 inhibitory.	 Ectopic	 expression	 of	DKK3	 in	 the	 PCa	 cell	 lines	 PC3,	
DU145	and	LNCaP	induces	apoptosis	via	phosphorylation	of	JNK,	reduction	of	Bcl-2	and	Bcl-xl	
levels,	 displacement	of	BAX	 to	 the	mitochondrial	membrane	and	 release	of	 cytochrome	c	
[207].	 In	 contrast,	 recombinant	 Dkk-3	 does	 not	 affect	 the	 proliferation	 or	 viability	 of	 the	
prostate	or	PCa		cell	lines	(PrEC,	PrSC,	BPH-1	LNCaP,	and	PC3)	[208].	Moreover,	other	groups	
have	 stably	overexpressed	DKK3	 in	BPH-1,	 LNCaP	and	PC-3	cells	 [208],	and	not	 found	any	







described	 in	 studies	 on	 diabetes	 and	 liver	 steatosis	 (the	 accumulation	 of	 fat	 in	 the	 liver),	
where	Dkk-3	 is	 implicated	as	an	 inhibitor	of	 insulin	resistance	and	glucose	 intolerance	and	
shows	anti-inflammatory	effects.	In	this	case,	Dkk-3	was	reported	to	interact	with	Apoptosis	
signal-regulating	kinase	1	(ASK1)	and	to	attenuate	p38/JNK	signalling	[211].		
		How	 Dkk-3,	 a	 secreted	 protein,	 can	 interact	 with	 ASK1,	 a	 cytoplasmic	 protein,	 remains	
unclear.	 However,	 there	 are	 several	 other	 reports	 of	 Dkk-3	 associating	 with	 cytoplasmic	
proteins,	such	as	β-TrCP,	a	negative	regulator	of	Wnt/β-catenin	[212].	In	prostate	cancer,	a	
yeast	 two-hybrid	 screen	 for	 Dkk-3-binding	 proteins	 identified	 small	 glutamine-rich	
tetratricopeptide	repeat-containing	protein	α	(SGTA),	which	is	a	negative	regulator	of	AR.	The	
interaction	 involved	 the	N-terminal	domains	of	Dkk-3	and	SGTA,	and	Dkk-3	was	 shown	 to	
	 42	
interfere	with	SGTA	dimerisation,	preventing	the	inhibition	of	AR.	As	it	was	previously	found	
that	Dkk-3	 interacts	with	 the	dynein	 light	chain	TCTEX-1,	 it	has	been	proposed	 that	Dkk-3	
promotes	the	dynein-dependent	transport	of	AR	and	 increases	AR	signalling	by	 interfering	
with	SGTA	dimerisation	[213].	The	physiological	relevance	of	these	interactions	remains	to	be	
determined.	 However,	 as	 mentioned	 above,	 an	 intracellular	 form	 of	 Dkk-3	 was	 recently	
described	[178].	
		In	support	of	the	secreted	form	of	Dkk-3	having	a	physiological	role,	one	study	found	the	
binding	 of	 Dkk-3	 to	 the	 surface	 and	 subsequent	 endocytosis	 in	 pluripotent	 stem	 cells	 of	
embryoid	 bodies	 [214].	 Moreover,	 zebrafish	 Dkk3	 has	 been	 found	 to	 associate	 with	 an	










cell	 layer.	 In	 BPH,	 Dkk-3	 expression	 in	 the	 basal	 layer	 has	 also	 been	 confirmed	 by	
immunofluorescence,	where	it	was	found	co-expressed	with	the	basal	cell	marker	p63	[208].	
In	low-Gleason-score	PCa,	Dkk-3	expression	in	epithelial	cells	is	mostly	maintained,	but	it	is	
significantly	 downregulated	 in	 high-Gleason-score	 PCa.	 Blood	 vessels	 also	 show	 the	
expression	of	Dkk-3	in	BPH	and	in	low-Gleason-score	PCa	[208].	Another	analysis	[207]	used	





as	 liver,	heart,	brain,	 lymph	node,	kidney,	spleen	and	mammary	gland)	[207].	 In	PCa,	as	 in	
most	human	cancers,	the	DKK3	gene	is	downregulated	by	promoter	methylation	[2].		
		Two	promoters	 for	 the	DKK3	gene	have	been	described,	 (a)	and	 (b)	 [216],	with	 (a)	being	
more	active	 than	 (b)	 in	most	 tissues	 [217].	 In	PCa,	promoter	 (a)	 is	more	methylated	 than	
promoter	 (b)	 [216].	Another	study	estimated	DKK3	promoter	hypermethylation	 in	primary	
PCa	to	be	78%	(n=41)	[190].	
		DKK3	gene	expression	can	be	restored	in	PCa	cell	lines	by	treatment	with	decitabine	(also	
known	 as	 5-aza-2ʹdeoxycytidine),	 a	 chemical	 analogue	 of	 the	 nucleoside	 cytosine	 (which	
inhibits	DNMT	 at	 low	 doses,	 causing	 DNA	 hypomethylation)	 and	 the	 histone	 deacetylase	























of	 the	 immortalised	prostate	epithelial	 cell	 line	RWPE-1	 to	compare	cells	 transfected	with	






examining	 Dkk3	 null	 mice)	 revealed	 morphological	 changes	 in	 the	 prostate	 gland	 and	





















		Dkk-3	 is	 not	 only	 expressed	 in	 the	 prostate	 epithelium	 but	 has	 also	 been	 found	 in	 the	
prostate	 stroma	 and	 prostate	 endothelium	 [208].	 Alterations	 in	 Dkk-3	 expression	 in	 the	




environment	 using	 lentiviral-delivered	 DKK3	 overexpression	 and	 shRNA-mediated	 DKK3	
knockdown	in	primary	prostate	stromal	cells	[226].	Dkk-3	has	been	found	to	participate	 in	





to	 myofibroblast	 differentiation,	 as	 demonstrated	 by	 decreases	 in	 SMA	 and	 IGF	 binding	
protein	 3	 (IGFBP3)	 expression.	However,	 overexpression	 of	DKK3	 did	 not	 affect	 fibroblast	
differentiation.	 Stromal	 remodelling	 by	 Dkk-3	 affected	 PI3K/AKT	 signalling	 due	 to	 the	
inhibition	of	AKT	phosphorylation	[226].	
		In	 addition,	Dkk-3	has	been	 shown	 to	be	upregulated	 in	 the	 tumour	 endothelium	 in	 the	
prostate	 and	 other	 cancers,	 including	 pancreatic,	 melanoma,	 colorectal,	 glioma	 and	 non-
Hodgkin	lymphoma,	suggesting	a	role	for	Dkk-3	in	angiogenesis	[227-229].	Moreover,	there	is	
an	 association	 between	 Dkk-3	 and	 the	 expression	 of	 angiopoietin-1	 in	 primary	 prostate	










therapeutic	effects	on	various	human	cancer	 types,	 including	PCa.	For	example,	 	 in	a	case	
study,	 a	 64-year-old	 patient	 with	 CRPC	 and	 multiple	 pelvic	 and	 para-aortic	 lymph	 node	
metastases	was	 treated	 for	 two	years	with	Ad-REIC	 therapy	 injections	 into	 the	metastatic	
sites,	leading	to	shrinking	of	lesion	growth	in	the	lymph	nodes	and	reduced	PSA	levels	[231].	
In	addition,	this	study	highlighted	more	than	one	anti-cancer	mechanism	of	Dkk-3:	firstly,	Dkk-
3	 showed	 a	 selective	 toxicity	 to	 cancer	 cells	 and,	 secondly,	 it	 modulated	 the	 immune	







therapy	 in	 four	 escalating	 doses,	 either	 injected	 directly	 into	 prostate	 tumours	 or	 into	
metastatic	 lesions.	 Both	 patient	 groups	 showed	 significant	 reductions	 in	 PSA	 levels.	









stromal	 cells	 increase	 the	 expression	 of	 angiopoietins	 [226],	 which	 are	 involved	 in	 blood	
vessel	homeostasis.	Untergasser	et	al.	 first	 reported	the	potential	 role	of	Dkk-3	 in	 tumour	
angiogenesis	 [228].	 They	 found	 that	 the	 number	 of	 blood	 vessels	 expressing	 Dkk-3	 was	
increased	in	glioma,	high-grade	non-Hodgkin	lymphoma,	melanoma	and	colorectal	carcinoma	
	 47	
compared	 to	 in	 normal	 tissues.	 They	 further	 showed	 that	 endothelial	 tube	 formation	
decreased	after	the	downregulation	of	Dkk-3	and	increased	after	Dkk-3	the	overexpression,	
and	that	overexpression	of	Dkk-3	 in	melanoma	cells	 increased	microvessel	density	 in	vivo.	
Based	on	their	results,	they	proposed	that	Dkk-3	in	endothelial	cells	acts	as	a	differentiation	
factor	 involved	 in	 remodelling	 the	 tumour	 vasculature.	 The	 same	 group	 showed	 that	
increased	Dkk-3	expression	in	tumour	endothelial	cells	is	an	independent	predictor	of	disease-




with	 low	 vessel	 Dkk-3	 (7	 months).	 It	 was	 proposed	 that	 Dkk-3	 increased	 sensitivity	 to	
chemotherapy	drugs,	 such	 as	 5-fluorouracil	 or	 gemcitabine.	DKK3	was	 also	 identified	 in	 a	
screen	for	genes	specifically	upregulated	in	colorectal	cancer	tumour	endothelium	[227].		
		The	 exact	 function	 of	 Dkk-3	 in	 the	 endothelium	 remains	 unclear.	 However,	 it	 enhances	





vein	 endothelial	 (HUVEC)	 cells	 after	 the	 knockdown	 of	 AXL	 [235].	 Dkk-3	 has	 also	 been	
associated	with	VEGF	signalling.	Recently,	Busceti	et	al.	[236]	reported	that	Dkk-3	promoted	
tube	formation	by	HUVEC	cells	by	 increasing	VEGF	 levels	and	activating	VEGF	signalling	by	










		Zhang	 et	 al.	 [238]	 performed	 gain-of-function	 and	 loss-of-function	 studies	 in	 mice	 and	
showed	 that	 Dkk-3	 has	 a	 protective	 effect	 against	 familial	 dilated	 cardiomyopathy.	 The	
beneficial	effects	were	associated	with	the	inhibition	of	apoptosis	signal-regulating	kinase	1-
c-Jun	N-terminal	 kinase	 (ASK1-JNK)	 /p38	 signalling.	They	also	 showed	 that	Dkk-3	based	 to	
ASK1	 and	 that	 dominant-negative	 ASK1	 rescued	 pressure	 overload-induced	 cardiac	










[244]	 found	 that	 Dkk3	 ablation	 in	 mice	 attenuates	 the	 development	 of	 atherosclerosis	
because	Dkk-3	expressed	by	macrophages	modulates	inflammation	and	inactivates	Wnt/β-
catenin	 signalling.	 In	 contrast,	 Yu	 et	 al.	 [245]	 reported	 a	 protective	 role	 for	 Dkk-3	 in	
atherosclerosis,	finding	that	the	level	of	the	plasma	Dkk-3	protein	is	inversely	related	to	this	



















































		Another	 in	 vitro	 co-culture	 model	 combined	WPMY-1	 cells	 with	 DU145	 cells	 [258].	 The	
authors	showed	that	DU145	cells	metabolise	stromal-derived	factors	to	generate	ligands	for	
ERβ,	 which	 can	 upregulate	 E-cadherin	 and	 limit	 DU145	 cell	 motility.	 However,	 unlike	
fibroblasts,	WPMY-1	cells	did	not	affect	DU145	cell	motility	because	the	DU145	cells	induced	
the	WPMY-1	cells	to	produce	H2O2,	which	acted	as	a	second	paracrine	factor	to	inhibit	ERβ	in	
DU145	 cells.	 This	 second	 signal	 was	 dependent	 on	 the	 presence	 of	 TGF-β1.	 The	 authors	











fibronectin	 [260].	 It	 functions	 in	 many	 physiological	 processes,	 including	 inflammation,	
wound	healing	and	bone	 formation.	The	 regulation	of	TGFBI	by	TGF-β	 signalling	has	been	
demonstrated	 in	a	variety	of	cell	 types,	 including	 fibroblasts,	smooth	muscle	cells,	corneal	
epithelial	 cells,	 chondrocytes	 and	 cancer	 cells.	 In	 addition,	 TGFBI	 can	 be	 induced	 by	 IL-1,	
retinoids,	TNF-α	and	lysophosphatidic	acid	[260].	
		Alterations	 in	 TGFBI	 are	 associated	 with	 many	 diseases,	 including	 diabetes,	 corneal	




[260].	 In	 cancer,	 TGFBI	has	dual	 functions	 as	 a	 tumour	 suppressor	 and	 tumour	promoter,	
dependent	on	cell	context	and	the	micro-environment.	For	example,	 in	ovarian	cancer	cell	
lines	 re-expression	 of	 TGFBI	 induces	 cancer	 cell	 death,	whereas	 high	 TGFBI	 expression	 in	
peritoneal	 cells	 promotes	 metastasis	 [260].	 TGFBI	 has	 also	 been	 found	 to	 regulate	 the	




apoptosis	 [262].	 TGFBI	 overexpression	 in	 CHO	 cells	 reduces	 proliferation	 and	 attenuates	
tumour	growth	 in	nude	mice.	Of	note,	ectopically	expressed	TGFBI	 is	processed	 in	vivo	 to	
remove	its	RGD	motif	[263].	On	the	other	hand,	TGFBI	has	a	tumour-promoting	effect	in	lung,	
kidney,	 pancreatic,	 colon,	 ovarian,	 brain	 and	 oesophageal	 cancers	 [260].	 In	 colorectal	
tumours,	the	level	of	TGFBI	correlated	with	lymph	node	metastases,	distant	metastases	and	
low	 overall	 survival,	 and	 it	was	 concluded	 that	 TGFBI	 is	 an	 independent	marker	 for	 poor	
prognosis	[264].	TGFBI	upregulation	is	also	an	indicator	for	poor	prognosis	 in	renal	cancer,	
where	changes	in	cell	adhesion	regulated	by	TGF-β	play	an	important	role	[265].	






















In	addition,	 the	 level	of	 ECM-1	 in	 testicular	 seminal	 fluid	has	been	considered	a	potential	
biomarker	for	azoospermia	[269].		There	are	four	alternatively	spliced	forms	of	ECM-1	(Figure	
1.7),	 with	 ECM-1a	 being	 the	most	 highly	 expressed	 in	 most	 of	 the	 tissues,	 including	 the	






basement	 membrane	 proteins	 that	 also	 contains	 collagen	 IV	 and	 laminin.	 Fibulins	 are	






and	 poor	 prognosis.	 In	 others,	 however,	 such	 as	 hepatocellular	 carcinoma	 (HCC),	 gene-
silencing	 experiments	 revealed	 that	 downregulation	 of	 ECM-1	 increases	 cancer	 cell	
proliferation	in	colony	formation	assays	and	is	associated	with	increased	MMP9	expression	
[274].	Importantly,	the	micro-environment	and	surrounding	stroma	are	expected	to	modulate	
the	 impact	 of	 ECM-1	 on	 tumour	 cell	 invasion	 and	 metastasis,	 particularly	 as	 MMPs	 are	





















3. Identify	 secreted	 proteins	 whose	 levels	 change	 upon	 DKK3	 silencing	 in	 prostate	
stromal	and	epithelial	cells.	
4. Examine	 the	 expression	 of	 Dkk-3	 in	 epithelial	 and	 stromal	 cells	 in	 prostate	 cancer	













general	 cells	were	 tested	 for	mycoplasma	 (Mycoplasma	Detection	 Kit,	 Lonza)	 every	 three	
months.	 	 The	 immortalised	 prostate	 stromal	 cell	 line	WPMY-1	 [253]	 was	 provided	 by	 Dr	
Richard	Morgan	(University	of	Surrey).	They	were	cultured	in	DMEM	(Life	Technologies)	with	
10%	FCS	(First	Link	Ltd.)	and	antibiotics	(100	units/ml	penicillin	and	100	ug/ml	streptomycin,	
Sigma).	 Equal	 numbers	 of	 cells	 were	 plated	 (2.5	 x	 105	 –	 4.5	 x	 105	 per	 25	 cm²	 flask)	 and	
passaged	when	close	 to	confluent	 (every	2-3	days).	Early	passage	cells	were	 thawed	 from	
liquid	nitrogen	every	4	months.	The	immortalised	normal	prostate	epithelial	cell	line	RWPE-1	
[224]	 was	 directly	 purchased	 from	 ATCC	 (LGC	 Standards,	 Teddington,	 UK	 and	 Barcelona,	
Spain).	Cell	 lines	derived	 from	RWPE-1	 (NS11,	NS14,	 sh6,	 sh30)	were	generated	 in	 the	 lab	
[160].	 RWPE-1	 cell	 lines	 were	 cultured	 in	 keratinocyte	 serum-free	 medium	 (KSFM)	











ug/ml)	 and	media	were	 changed	 every	 2	 days.	 A	 dose	 of	 1.5	 ug/ml	was	 identified	 as	 the	
minimum	dose	required	to	kill	100%	of	cells	in	1	week.	WPMY-1	cells	were	transfected	with	
the	 DNA	 plasmids	 pSM2	 shRNAmir	 DKK3	 (RHS1764-9689535)	 and	 pSM2	 shRNAmir	 non-
silencing	 control	 (RHS1703)	 plasmids	 (Open	 Biosystems,	 now	 Thermo	 Fisher	 Scientific,	






























in	 their	 respective	 growth	 media	 for	 48	 h	 prior	 to	 preparation	 of	 cell	 extracts.	 In	 some	
experiments,	media	were	changed	to	serum-free	media	with	or	without	10	ng/ml	TGF-β	for	
24	h.	For	collection	of	conditioned	medium	(CM),	media	were	centrifuged	at	500	g	for	5	min	









overnight	 and	 then	 the	media	was	 changed	 to	1	ml	of	 the	 appropriate	 serum-free	media	









1	 h.	 Primary	 antibodies	 (listed	 in	Supplementary	 Table	 3)	 diluted	 in	 blocking	buffer	were	
added	and	membranes	incubated	on	a	rocker	in	the	cold	room	overnight.	The	membranes	
were	 then	 washed	 at	 least	 3	 times	 for	 5	 min	 in	 TBST	 on	 a	 shaker,	 incubated	 with	 HRP-
conjugated	secondary	antibodies	(listed	in	Supplementary	Table	4)	diluted	in	blocking	buffer	
for	 1	h,	washed	3	 times	 for	 15	min	 and	 then	 incubated	with	ClarityTM	Western	Enhanced	







re-suspended	 in	 1	 ml	 of	 Trizol	 reagent	 (Invitrogen).	 Following	 the	 addition	 of	 200	 μl	
chloroform,	samples	were	incubated	at	RT	for	5	min	and	were	then	shaken	for	15-30	seconds	


















6	 μl	 of	 reverse-transcription	master	mix	 (1	 μl	 Quantiscript	 Reverse	 Transcriptase,	 4	 μl	 5x	





the	 7900HT	 Fast	 Real-Time	 PCR	 thermal	 cycler	 (Applied	 Biosystems).	 1	 μg	 total	 RNA	was	
reverse	transcribed	as	described	above,	2	μl	of	cDNA	was	added	to	a	reaction	mix	consisting	














incubated	 for	 20	 min.	 Cell	 media	 were	 replaced	 with	 500	 ul	 of	 OptiMEM	 and	 200	 ul	 of	
















morphogenesis	 was	 evaluated	 as	 described	 in	 other	 studies	 [160,	 177].	 5	 photos	 (100	 x	
magnification)	per	well were	taken	at	days	4,	6,	7	and	8	using	an	Axiovert	S	100	microscope	
(Zeiss)	 and	 processed	with	MetaMorph	 (Molecular	 Devices)	 or	 using	 an	 Eclipse	 TE2000-U	
microscope	(Nikon)	and	Image-Pro	(Media	Cybernetics	Inc.).	The	numbers	of	regular,	notched	
and	deformed	acini	were	counted	using	ImageJ	software.	Each	experiment	was	repeated	in	















































with	 0.2%	 Crystal	 violet	 in	 20%	 MeOH	 and	 at	 least	 5	 pictures	 taken	 per	 insert	 at	 100x	
magnification	 using	 an	 Eclipse	 TE2000-U	 microscope	 (Nikon)	 and	 Image-Pro	 (QImaging,	
Surrey,	BC,	Canada).	Image	J	software	was	used	to	count	the	numbers	of	invaded	cells.												




































































Vectastain	 Elite	 ABC	 Standard	 kit	 (Vector),	 according	 to	 manufacturer's	 instructions	
(Supplementary	Table	2.8),	with	the	chromogenic	reaction	performed	using	1	ml	ImmPACT	
DAB	(Vector)	per	slide	(2	min	for	Dkk-3,	pan-cytokeratin	and	TGFBI	and	5	min	for	ECM-1).	




with	 Permount	 in	 a	 fume	 hood	 for	 30	 min.	 Pictures	 were	 taken	 using	 a	 Leica	 DM750	
microscope	at	different	magnifications	(10x	to	40x).		
Statistical	analysis	
		Paired	 Student’s	 t-test	was	 carried	 out	 using	Microsoft	 Excel.	 Statistical	 significance	was	
considered	for	p	<	0.05.	Two-Way	ANOVA	and	Tukey’s	multiple	comparison	was	done	using	
Graphpad	 Prism	 version	 6	 for	 multiple	 comparisons	 in	 acinar	 morphogenesis	 assays.	

























		The	 mechanism	 of	 the	 action	 of	 Dkk-3	 has	 been	 investigated	 in	 vitro	 using	 different	
approaches,	 including	overexpression	of	DKK3	using	plasmid	and	adenoviral	 vectors,	 gene	
silencing	of	DKK3	using	 siRNAs	and	 shRNA	expression	vectors,	 and	by	addition	of	purified	
recombinant	 DKK3	 protein	 (rhDkk3)	 [172,	 226].	 Studies	 in	 our	 laboratory	 used	 plasmids	
expressing	control	and	DKK3-specific	shRNAs	to	generate	silenced	clones	of	RWPE-1	prostate	
epithelial	 cells	 [172].	 Here,	 I	 have	 used	 the	 same	 approach	 to	 silence	 DKK3	 in	 WPMY-1	
prostate	stromal	cells,	with	the	aim	of	determining	the	function	of	Dkk-3	in	prostate	stromal	
cells	and	on	the	role	of	stromal	Dkk-3	on	prostate	epithelial	and	cancer	cell	function,	which	
might	help	explain	how	Dkk-3	acts	as	a	 tumour	suppressor.	 In	 this	chapter,	 I	describe	 the	
generation	 of	 the	 WPMY-1	 cell	 lines	 expressing	 control	 and	 DKK3	 shRNAs	 and	 their	





plasmids	 expressing	 control	 and	 DKK3	 shRNAs	 and	 selected	 stable	 cell	 lines	 for	 further	
analysis.	For	the	control	shRNA,	4	pooled	clones	of	cells	were	selected,	and	for	DKK3	shRNA,	
11	single	cell	clones	were	selected.	An	optimal	dose	of	puromycin	for	selection	in	WPMY-1	














approximately	 56	 kDa	 (Figure	 3.1B),	 like	 what	 was	 previously	 observed	 in	 RWPE-1	 cells.	
Considering	the	GAPDH	 loading	control,	Dkk-3	 levels	were	similar	 in	extracts	of	PSM2	and	
NPSM2	cells	as	in	extracts	of	parental	WPMY-1	cells,	while	they	were	much	lower	in	extracts	
of	Wsh7	and	Wsh8	cells	 (Figure	3.1B).	Densitometry	analysis	 indicated	 that	Dkk-3	protein	
levels	were	about	11-fold	lower	in	Wsh8	cells	and	9-fold	lower	in	Wsh7	cells,	compared	to	
WPMY-1	cells	(Figure	3.1C).	








line	 PSM3,	 compared	 to	Wsh8,	was	 also	 confirmed	by	western	 blotting	 (Figure	 3.1F)	 and	
densitometry	(Figure	3.1G),	was	approximately	30-fold	lower	in	Wsh8	CM	and	extract	than	in	




		Since	 silencing	of	Dkk-3	has	been	observed	 to	 increase	TGF-β/Smad	signalling	 in	RWPE-1	
cells,	with	increased	levels	and	phosphorylation	of	Smad2	[160],	and	WPMY-1	cells	have	been	


































revealed	 that	DKK3	 silencing	 further	 increased	endogenous	 TGF-β/Smad	 signalling	 (Figure	
3.4B).	











MMP2	 and	 α-SMA.	 MMP2	 was	 chosen	 because	 it	 is	 elevated	 in	 DKK3-silenced	 prostate	
epithelial	 cells	 [161],	 and	 α-SMA	 was	 chosen	 because	 it	 is	 affected	 by	 DKK3	 in	 primary	
prostate	stromal	cells	[226].	MMP2	levels	in	WPMY-1	cell	extracts	were	low,	with	more	MMP2	
detected	in	WPMY-1	cell	CM	than	in	cell	extracts	(Figure	3.5A).	MMP2	levels	in	cell	extracts	
were	not	 significantly	 affected	by	DKK3	 silencing.	 There	was	 a	 trend	 for	 increased	MMP2	
levels	in	CM	from	TGF-β1-treated	Ctrl	shRNA	cells	and	also	a	trend	for	higher	basal	MMP2	
levels	in	CM	from	DKK3-silenced	cells	(Wsh8),	compared	to	control	cells	(Figure	3.5B).	α-SMA	
was	 detected	 by	 western	 blotting	 in	 WPMY-1	 cell	 extracts	 (Figure	 3.5C).	 However,	
densitometry	analysis	indicated	that	there	was	no	significant	effect	of	DKK3	silencing	or	TGF-
β1	treatment	on	α-SMA	levels	(Figure	3.5D).	
		In	 summary,	 TGF-β	 signalling	 appears	 to	 be	 active	 in	 WPMY-1	 cells	 and	 DKK3	 silencing	
increases	the	levels	of	Smad3	and	the	activity	of	the	CAGA12-luciferase	reporter.	However,	





Interestingly,	while	 TGF-β	 treatment	 of	 cells	 did	 not	 affect	Dkk-3	 levels	 in	 cell	 extracts,	 it	
increased	Dkk-3	 levels	 in	cell	CM	both	 from	control	and	DKK3-silenced	cells	 (Figure	3.6A).	
Densitometry	 analysis	 indicated	 that	 TGF-b	 treatment	 resulted	 in	 an	approximately	2-fold	















plates	 in	 triplicate	 and	 stained	 and	 analysed	 at	 days	 1,	 3,	 5	 and	 7	 (Figure	 3.7A).	 The	
proliferation	of	the	cell	lines	was	similar,	without	significant	differences	throughout	the	time	





















literature,	 to	be	 regulated	by	DKK3,	and	compared	 the	effects	of	DKK3-silencing	on	 those	
genes	 in	 RWPE-1	 and	WPMY-1	 cells.	 The	 genes	 that	 were	 examined	were	ACTG2,	 which	
encodes	smooth	muscle	actin	and	is	 important	for	smooth	muscle	cell	differentiation	[44],	









addition,	 given	 that	 Dkk-3	 can	 promote	 embryonic	 stem	 cell	 differentiation	 into	 smooth	
muscle		[281]	and	that	RWPE-1	cell	cultures	contain	a	stem	cell	population	[282],	I	examined	









highly	 expressed	 in	WPMY-1	 cells	 than	 in	 RWPE-1	 cells	 (Figure	 3.9A).	 Next,	 the	 extent	 of	
silencing	of	DKK3	was	determined	in	RWPE-1	control	(NS11)	and	DKK3-silenced	(sh6)	cells.	
This	showed	that	the	expression	of	DKK3	in	sh6	cells	was	12%	of	that	in	NS11	cells	(Figure	
3.9B).	 Analysis	 of	 the	 other	 genes	 revealed	 that	 DKK3	 silencing	 significantly	 increased	






















control	 and	 DKK3-silenced	 RWPE-1	 and	WPMY-1	 cells	 were	 transfected	with	 GFP	 vectors	
driven	by	the	s-SHIP	promoter	[276].	As	a	control,	a	constitutive	promoter	(CMV)	driving	GFP	







3.1%	 for	NS11	 and	 sh6,	 respectively,	 in	 the	 first	 experiment	 and	 0.28%	 and	 0.12%	 in	 the	
second	experiment.	These	percentages	were	normalised	to	those	from	cells	transfected	with	
CMV-GFP,	which	in	the	first	experiment	was	34%	and	37%	for	NS11	and	sh6,	respectively,	and	
in	 the	 second	 experiment	 was	 1.8%	 and	 1.2%.	 The	 normalised	 results	 indicated	 that	 the	












on	 the	 expression	 of	 s-SHIP	 in	 RWPE-1	 and	WPMY-1	 cells.	 These	 interesting	 observations	







not	affect	proliferation	 in	either	cell	 line,	but	 it	does	 increase	WPMY-1	cell	migration	 (the	
effect	of	DKK3	silencing	on	RWPE-1	cell	migration	has	not	been	tested).	 In	both	cell	types,	






























prostate	 tumours	 [177].	 Ectopic	 expression	 of	 Dkk-3	 reduces	 prostate	 cancer	 cell	
proliferation,	suggesting	that	the	reduction	in	Dkk-3	in	prostate	tumours	plays	a	role	in	cancer	
progression	 [160,	 177].	 Interestingly,	 Dkk-3	 levels	 have	 been	 reported	 to	 be	 increased	 in	
prostate	cancer	stroma	[226].	However,	it	is	not	clear	if	stromal	Dkk-3	plays	a	protective	or	






increases	 TGF-β/Smad	 signalling	 in	 this	 cell	 line.	 In	 this	 chapter,	 I	 describe	 experiments	
determining	the	effects	of	conditioned	media	(CM)	from	control	and	DKK3-silenced	WPMY-1	
cells,	or	of	the	cells	themselves,	on	RWPE-1	cell	proliferation	and	acinar	morphogenesis	and	







stromal	 cells	 and	WPMY-1	 cells	 expressing	 control	 shRNA	 (NPSM2	 and	 PSM2)	 and	 DKK3	
shRNA	(Wsh7,	Wsh8).	
		To	 study	 the	 effects	 of	 stromal	 Dkk-3	 on	 RWPE-1	 cells,	 conditioned	 media	 (CM)	 were	
collected	from	WPMY-1	stromal	cells	that	had	been	cultured	in	RWPE-1	cell	culture	medium	





































(Figure	 4.3B),	 as	 compared	 to	 medium	 alone.	 NPSM2	 CM	 also	 increased	 the	 number	 of	
normal	acini	formed	by	NS11	cells	(Figure	4.3B).	In	contrast,	Wsh8	CM	reduced	the	number	
of	 normal	 acini	 formed	 by	 NS11	 cells	 and	 showed	 a	 trend	 for	 increasing	 the	 number	 of	
notched	 acini	 (Figure	 4.3A).	 However,	 Wsh7	 CM	 did	 not	 significantly	 affect	 acinar	
morphogenesis	of	NS11	cells,	when	compared	to	medium	alone	(Figure	4.3B).	In	experiments	
using	NS14	cells,	NPSM2	CM	slightly	 increased	 the	number	of	normal	acini	and	Wsh7	CM	
reduced	 the	 number	 of	 normal	 acini	 and	 showed	 a	 trend	 for	 increasing	 the	 numbers	 of	
notched	and	deformed	acini,	compared	to	control	medium	(Figure	4.3C).	


























		Although	DKK3	 silencing	 in	RWPE-1	 cells	does	not	affect	 their	proliferation	 in	monolayer	
cultures,	it	increases	their	proliferation	in	3D	cultures,	and	this	is	thought	to	contribute	to	the	





are	 invading	 the	 reactive	 stroma,	 which	 has	 been	 induced	 to	 express	 Dkk-3	 [226].	
Interestingly,	sh30	cell	proliferation	was	significantly	higher	upon	co-culture	with	Wsh8	cells,	
as	 compared	 to	 co-culture	 with	 NPSM2	 cells	 or	 with	medium	 alone	 (Figure	 4.4B).	 These	
results	indicate	that	the	proliferation	of	DKK3-silenced	RWPE-1	cells	is	not	affected	by	the	co-
culture	of	 control	WPMY-1	 cells,	 but	 is	 increased	by	 co-culture	of	DKK3-silenced	WPMY-1	





















CM	 from	WPMY-1	 cells	 (Figure	 4.5A).	 A	 similar	 result	was	 observed	when	 comparing	 the	
invasion	 of	 PC3	 cells	 in	 the	 presence	 of	 CM	 from	DKK3-silenced	Wsh7	 cells	 and	 CM	 from	
NPSM2	cells	(Figure	4.5B).	Interestingly,	there	were	no	significant	differences	in	the	invasion	
of	PC3	cells	cultured	in	medium	alone	compared	to	culture	in	the	presence	of	CM	from	WPMY-
1	 cells	 or	 NPSM2	 cells.	 Together,	 these	 results	 are	 consistent	 with	 a	 model	 in	 which	 the	




WPMY-1	 cells	 express	 high	 levels	 of	MMP2	 [253],	 and	 Dkk-3	 regulates	 prostate	 epithelial	






















































































































































































1	 cells	 in	 a	 Dkk-3-dependent	manner.	 In	 addition,	 CM	 from	 DKK3-silenced	WPMY-1	 cells	
increased	PC3	cell	invasion	in	an	MMP2-dependent	manner.	These	results	suggest	that	DKK3	
















both	 cases	 printed	 in	 duplicate.	 Arrays	were	 incubated	with	 CM	 from	 control	 and	 DKK3-


























		In	 summary,	 the	 array	data	 indicate	 that	CM	 from	DKK3-silenced	WPMY-1	 cells	 contains	
more	TGFBI	and	slightly	less	ECM-1,	IL-8	and	MMP2	than	CM	from	control	WPMY-1	cells.	
		A	parallel	analysis	was	performed	by	Dr	Diana	Romero	using	CM	from	control	(NS11)	and	
























indicated	 that	 the	 level	 of	 TGFBI	 was	 higher	 in	 Wsh8	 cell	 CM	 than	 in	 PSM2	 cell	 CM.	











































		In	 order	 to	 determine	 the	 functional	 effects	 of	 increased	 levels	 of	 TGFBI	 and	 ECM-1	 on	
prostate	 cells,	 purified	 recombinant	 human	 TGFBI	 (rhTGFBI)	 and	 ECM-1	 (rhECM-1)	 were	
added	 to	 control	 and	DKK3-silenced	RWPE-1	 cells	 in	 acinar	morphogenesis	 assays.	 To	use	
physiologically	 relevant	 amounts	 of	 recombinant	 proteins	 in	 these	 experiments,	 western	












morphogenesis,	 with	 a	 significant	 increase	 in	 normal	 acini	 and	 a	 significant	 reduction	 in	
deformed	acini.	The	numbers	of	notched	acini	were	similar	in	control	and	treated	cells.	
		The	results	of	experiments	performed	in	control	(NS11)	cells	indicated	that	treatment	with	




		In	 summary,	 rhECM-1	 rescued	 acinar	 morphogenesis	 in	 DKK-3-silenced	 cells,	 whereas	
















PC3	 cell	 invasion	 assays	 were	 carried	 out	 in	 the	 control	 medium	 or	 medium	 containing	











































			In	2006,	an	 immunohistochemical	 study	 from	our	group	using	a	commercial	TMA	 found	
heterogeneous	expression	of	Dkk-3	in	prostate	cancer	[177].	Statistical	analysis	of	the	results	
indicated	significantly	 lower	Dkk-3	expression	 in	 tumours	with	a	Gleason	score	of	9	or	10,	
compared	to	Gleason	scores	of	8	and	below,	suggesting	that	loss	of	Dkk-3	corresponds	with	
the	loss	of	glandular	structure.	Similar	results	were	reported	by	other	groups	[207,	208].	It	is	
well-established	 that	 patients	 with	 poorly	 differentiated	 non-metastatic	 tumours	 have	 a	
lower	overall	 survival	 rate,	compared	with	patients	with	well-differentiated	 tumours	 [287,	




		In	 this	 Chapter,	 I	 describe	 results	 from	 immunohistochemical	 examination	 of	 Dkk-3	
expression	in	the	epithelia	and	stroma	of	benign	and	tumour	tissue	sections	from	prostate	
cancer	patients,	and	compare	them	with	the	expression	patterns	of	TGFBI	and	ECM-1.	For	this	
study,	 tissue	 microarrays	 (TMAs)	 from	 the	 Imperial	 Cancer	 Biomarker	 Resource	 Centre	
(ICBRC)	were	subjected	to	immunohistochemistry	with	a	panel	of	antibodies.	In	addition	to	
using	 antibodies	 recognising	 Dkk-3,	 epithelial	 cytokeratin,	 TGFBI	 and	 ECM-1,	 for	 which	 I	














myofibroblasts	 (reactive	 stroma)	 [289].	 The	 TMAs	 were	 also	 stained	 using	 anti-pan	
cytokeratin	 (CK)	 antibodies	 to	 detect	 normal	 and	 tumour	 epithelial	 cells,	 and	 with	
Haematoxylin	and	Eosin	(H&E)	to	reveal	tissue	morphology	(Figure	6.1C).	Haematoxylin	is	the	
deep	purple	staining	that	detects	nucleic	acid,	while	eosin	 is	the	pink	staining	that	detects	
proteins	 [290].	 In	 this	 study,	 the	 “quick	 scoring”	method	 [291],	 in	 which	 the	 intensity	 of	
staining	is	scored	visually	and	given	a	number,	was	used	by	two	people	(Zainab	Al	Shareef	and	
Robert	Kypta).	 In	addition,	 the	TMAs	were	 re-analysed	by	a	pathologist	 (James	Carton)	 to	
confirm	the	section	Gleason	scores.		













		Not	 all	 the	 patient	 tumour	Gleason	 scores	 corresponded	with	 the	Gleason	 scores	 of	 the	
sections	analysed	by	immunohistochemistry.	Among	the	differences	were	8	patient	tumour	
sections	that	contained	only	benign	tissue.	These	were	therefore	excluded	from	the	analysis,	
















































tumour	epithelium	 (red	arrow)	and	absent	 (score	0)	 in	 the	 tumour	 stroma	 (green	arrow),	
although	it	was	detected	in	endothelial	cells	(blue	arrow).	
		For	statistical	analysis,	scores	of	0	and	1	were	classified	as	low	Dkk-3	and	scores	of	2	and	3	
were	 classified	as	high	Dkk-3.	 The	 results	 (Table	6.2)	 indicated	 that	Dkk-3	expression	was	
































tumour	 stroma.	 Higher	 magnification	 images	 (Figure	 6.6B)	 show	 expression	 of	 TGFBI	 in	
benign	prostate	basal	and	luminal	epithelial	cells,	as	well	as	in	some	stromal	cells.	
		For	statistical	analysis,	scores	of	0	and	1	were	classified	as	low	TGFBI	and	scores	of	2	and	3	










shows	 examples	 of	 each	 category	 of	 ECM-1	 score	 in	 prostate	 epithelium,	 using	 pan-CK	
staining	of	adjacent	sections	to	identify	the	epithelial	cells.	ECM-1	expression	in	the	stroma	
was	 scored	 in	 a	 similar	manner,	 separately	 (Figure	 6.7B).	 There	 was	 a	 problem	with	 the	
immunohistochemical	 reaction	 for	 some	of	 the	 TMAs,	 so	 only	 67	 of	 the	 prostate	 tumour	
samples	could	be	analysed.	ECM-1	expression	in	the	stroma	was	generally	weak	(score	1)	or	
undetectable	(score	0),	with	a	score	of	2	observed	 in	only	5	benign	stroma	sections	and	2	




epithelium	 than	 in	 benign	 epithelium.	 However,	 the	 majority	 of	 the	 benign	 and	 cancer	
sections	expressed	moderate	levels	of	epithelial	ECM-1	(score	2).	
		Examples	of	ECM-1	staining	in	patients	are	shown	in	(Figure	6.8).	Patient	1	in	Figure	6.8A	

























and	 high	 expression	 of	 Dkk-3	 in	 the	 cancer	 epithelium,	 and	 Figure	 6.9B	 shows	 a	 tumour	
section	from	a	patient	with	high	expression	of	TGFBI	and	low	expression	of	Dkk-3	in	the	cancer	
epithelium.	In	addition,	TGFBI	was	expressed	in	the	cancer	stroma.	










































		The	patient	data	available	 for	 the	 Imperial	College	TMAs	did	not	 include	any	 information	
about	 patient	 survival.	 Therefore,	 to	 determine	 if	 there	 might	 be	 a	 link	 between	 the	
expression	of	Dkk-3,	TGFBI	or	ECM-1	and	patient	survival,	their	gene	expression	patterns	were	
analysed	 using	 PROGgene,	which	 provides	 patient	 survival	 data	 for	many	 types	 of	 cancer		
(http://watson.compbio.iupui.edu/chirayu/proggene/database/index.php).	The	PCa	dataset	
GSE70768	[292]	was	used	because	it	contains	a	sufficient	number	of	relapses	for	statistical	
analysis.	 Correlation	 of	 gene	 expression	 with	 respect	 to	 relapse-free	 survival	 of	 prostate	
cancer	patients	(n	=	110)	was	analysed	by	taking	the	median	gene	expression	value	for	each	
gene	and	then	dividing	patients	 into	high	(above	the	median)	and	low	(below	the	median)	











and	11/45	 low	expressors	 relapsing	 (p	=	0.17,	not	shown),	and	a	second	dataset	 from	the	
same	 study	 (GSE70769;	n	=	91),	 showed	higher	 relapse-free	 survival	 in	patients	with	high	
ECM1	expression	(p	=	0.03),	with	20/46	high	expressors	and	25/45	low	expressors	relapsing	
(Figure	 6.12C).	 A	 another	 dataset	 [293]	 (MSKCC)	 was	 analysed	 for	 patient	 survival	 using	
camcAPP	 (http://bioinformatics.cruk.cam.ac.uk/apps/camcAPP/)	 [294].	 This	 also	 showed	 a	
correlation	between	low	DKK3	expression	and	reduced	patient	survival	(p=0.021,	not	shown)	
but	there	was	no	correlation	for	ECM1	or	TGFBI.	
		The	DKK3	 gene	 expression	 results	 are	 consistent	with	 the	 TMA	 results,	which	 showed	 a	
reduction	in	Dkk-3	expression	in	high	Gleason	grade	prostate	tumours.	The	TGFBI	and	ECM1	
gene	expression	results	seem	to	contrast	with	the	results	from	the	TMAs,	where	both	proteins	
were	more	 highly	 expressed	 in	 cancer.	However,	 TGFBI	 and	 ECM-1	 protein	 levels	 did	 not	










test	 sections	 when	 the	 different	 antibodies	 were	 being	 assessed	 for	 use	 in	
immunohistochemistry.	In	addition,	it	 is	likely	that	Jenny	Steel	carried	out	negative	control	
staining	 of	 the	 TMAs	 when	 staining	 for	 SMA	 and	 Vimentin,	 but	 as	 she	 has	 taken	 early	
retirement,	this	cannot	be	confirmed.	The	second	caveat	is	regarding	the	fact	that	there	are	






there	were	 nine	 patient	 samples	 in	 the	 TMA	 that	 did	 not	 contain	 tumour	 cells	 and	were	
excluded	from	the	analysis.	This	should	not	affect	the	correlation	of	expression	of	Dkk-3,	ECM-








higher	 in	cancer	than	 in	benign	epithelium.	Moreover,	 there	was	an	 inverse	correlation	of	
Dkk-3	and	TGFBI	expression	in	low	Gleason	score	(≤43)	PCa.	However,	in	low	Gleason	score	
PCa	 stroma,	 ECM-1	 showed	 positive	 correlations	 with	 Dkk-3	 and	 TGFBI.	 The	 DKK3	 gene	
expression	 results	 are	 consistent	 with	 the	 TMA	 results,	 showing	 a	 reduction	 in	 DKK3	
expression	 in	 high	 Gleason	 grade	 prostate	 tumours	 and	 a	 correlation	 of	 high	 DKK3	 with	
relapse-free	 survival.	 However,	 the	 gene	 expression	 data	 for	 TGFBI	 and	 ECM1	 were	 less	























similar	 genetic	 background	 than	 prostate	 stromal	 and	 epithelial	 cell	 lines	 from	 different	




additional	 prostate	 stromal	 and	 epithelial	 cell	 lines.	 I	 recently	 cultured	 a	 PShTert,	 a	























s-SHIP	 (Figure	 3.9),	 which	 are	 known	 to	 be	 expressed	 in	 stem/progenitor	 populations	 in	
epithelial	 cells.	 It	 is	 not	 known	 if	 these	 genes,	 and	 possibly	 ACTG2,	 are	 expressed	 by	 a	



































morphogenesis	 [160].	 There	 is	 considerable	 evidence	 for	 epithelial	 Dkk-3	 increases	
TGFβ/Smad	signalling	in	RWPE-1	prostate	epithelial	cells	[160,	299].	This	was	also	observed	




Smad2,	 not	 Smad3	 [160].	 This	 difference	might	 account	 for	 the	different	 effects	 of	Dkk-3	
silencing	on	the	proliferation	of	the	two	cell	types,	since	Smad2	and	Smad3	can	have	different	
effects	in	some	cell	systems	[111-113].		
		Dkk-3	 from	 WPMY-1	 CM	 also	 inhibited	 PC3	 cell	 invasion.	 The	 MMP2	 inhibitor	 ARP100	
inhibited	the	pro-invasive	effects	of	CM	from	DKK3-silenced	WPMY-1	cells,	suggesting	a	role	
for	MMP2,	 the	main	MMP	 family	member	 inhibited	 by	 ARP100	 at	 the	 dose	 used,	 in	 this	
response	to	Dkk-3.	This	finding	is	consistent	with	those	from	previously	published	work	from	
the	 lab	 showing	 that	 DKK3	 silencing	 increases	 MMP	 expression	 and	 activity	 in	 primary	
prostate	epithelial	cells	and	RWPE-1	cells	[161].	Therefore,	it	is	possible	that	Dkk-3	secreted	














Moreover,	our	 lab	has	shown	that	MMP	 inhibition	 in	Dkk-3-silenced	RWPE-1	cells	 rescues	
acinar	morphogenesis	and	inhibits	PC3	cell	invasion	[161],	consistent	with	the	anti-metastatic	
role	of	Dkk-3	involving	regulation	of	TGF-β-dependent	MMP	signals.	
		Despite	 the	 considerable	 evidence	 linking	 Dkk-3	 and	 TGF-β/Smad	 signalling,	 we	 do	 not	
understand	this	at	the	mechanistic	level.	Some	studies	have	led	to	the	proposal	that	Dkk-3	
acts	 intracellular	 [2].	A	very	 recent	 report	described	an	alternative	start	 site	 in	 the	mouse	




function,	 for	 example	 mediated	 by	 cell-surface	 Dkk-3	 receptors.	 Consistent	 with	 this,	
zebrafish	Dkk3	(Dkk3a)	has	been	shown	to	bind	to	zebrafish	α6	integrin	(Itga6b)	to	stimulate	
Myf5	 promoter	 activity	 during	 myogenesis	 [215,	 304].	 As	 Dkk3a	 is	 only	 42%	 identical	 to	

















in	 the	more	 than	60%	of	 prostate	 cancer	 patients	 [306].	Alterations	 in	 the	 level	 of	 TGF-b	
secreted	by	 fibroblasts	may	be	a	 critical	 step	 in	 switching	 fibroblasts	 to	 cancer-associated	
fibroblasts	 (CAFs)	 [306].	 This	 switch,	 which	 is	 thought	 to	 be	 linked	 to	 the	 loss	 of	 TΒRII	
expression,	which	alters	the	response	to	TGF-b,	could	be	affected	by	the	expression	level	of	
Dkk-3.	In	addition,	high-grade	tumours	(Gleason	8-10)	have	high	levels	of	MMP2	and	MMP9	
[307].	MMPs	secreted	by	stromal	cells,	 rather	 than	by	PCa	cells,	play	an	 important	 role	 in	
contributing	to	stromal	cell	promotion	of	cancer	cell	invasion	[308,	309].	The	amount	of	Dkk-
3	in	the	stroma	could	therefore	be	important	for	controlling	the	paracrine	effects	of	MMP2.		



































		The	 inverse	 correlation	 between	 TGFBI	 and	 Dkk-3	 in	 cancer	 was	 only	 observed	 in	 low	
Gleason	 score	 (<	 3,	 4)	 tumours,	 suggesting	 that	 the	 link	 between	Dkk-3	 and	 TGFBI	 is	 less	
important	as	tumours	become	more	advanced.	Indeed,	the	patient	survival	data	(Figure	6.12)	
suggest	 that	 high	 DKK3	 but	 not	 low	 TGFBI	 mRNA	 expression	 correlate	 with	 relapse-free	
survival	of	PCa	patients.	It	will	be	important	to	compare	TGFBI	and	Dkk-3	protein	levels	in	a	









there	was	 an	 increase	 in	 the	 level	 of	 TGFBI	 protein	 in	WPMY-1	 cells	 by	western	 blotting,	
















effects	 were	 clearer	 when	 CM	 were	 probed	 for	 ECM-1	 by	 western	 blotting	 (Figure	 5.4).	
However,	in	both	cell	types,	Dkk-3	silencing	had	no	effect	on	ECM1	mRNA	levels,	suggesting	
that	Dkk-3	silencing	affects	ECM-1	protein	stability	or	secretion.	Western	blotting	of	control	
and	 DKK3-silenced	 RWPE-1	 and	 WPMY-1	 cell	 extracts	 gave	 variable	 results	 in	 different	
experiments	and	were	therefore	not	presented	in	this	thesis.	In	WPMY-1	cell	extracts,	ECM-




		Although	ECM-1	has	been	 reported	 to	promote	 cancer	 cell	migration	 in	 several	 types	of	
cancer,	 its	mechanism	of	action	 in	cancer	 is	not	clear.	A	 recent	study	 in	metastatic	breast	







































lead	 to	 further	 disruption	 of	 the	 prostate,	 increased	 proliferation	 and	 PCa	 cell	 invasion.	
Regarding	 the	 role	 of	 ECM-1	 in	 this	 model,	 it	 could	 also	 form	 part	 of	 the	 Dkk-3	 stromal	
defence,	as	its	expression	correlates	with	that	of	Dkk-3	in	WPMY-1	cells,	it	inhibits	the	effects	
of	TGFBI	on	PC3	cell	 invasion	and,	 like	DKK3,	 its	gene	expression	correlates	with	increased	
relapse-free	 survival.	 To	 test	 this	model,	 it	will	 be	 important	 to	 confirm	 the	 results	 using	
additional	prostate	epithelial	 and	prostate	 stromal	 cell	 line	models,	 and,	 if	 possible,	using	
cultures	of	primary	prostate	stromal	and	epithelial	cells.	Ultimately,	 in	vivo	studies	in	mice	








Solution	 10%	gel	 8%	gel	 Stacking	gel	
dH2O	 5.9	ml	 6.9	ml	 	2.1	ml	
30%	acrylamide	mix	 5	ml	 4	ml	 	0.5	ml	
1.5	m	Tris	pH	8.8	 3.8	ml	 3.8	ml	 	0.38	ml	
10%	SDS	 150	 µl	 150	 µl	 	30	µl	
10%	APS	 150	 µl	 150	 µl	 	30	µl	
































Protein	 Reference	 Species	 Dilution	



















MMP2	 Invitrogen	 mouse	 1:400	(i)	1:1000	(w)	
Smad2	 Cell	Signaling	sampler	kit	#9963	 rabbit	 1:1000	(w)	
Smad3	 Abcam	ab40854	 Rabbit	 1:2000	(w)	
Smad4	 Cell	Signaling	sampler	kit	#9963	 rabbit	 1:1000	(w)	
phospho-Smad3	 R&D	AB3226	 mouse	 1:1000	(w)	

























ml	 1M	 Tris	 pH	 6.8,	
67.5	ml	dH2O	to	100	





50oC	 30	 min,	 shaking	







0.2	 M	 NaOH	 5	 min,	
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